Circulating Baseline CXCR3Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Objective: The high prevalence of osteoporosis in rheumatoid arthritis (RA) is due to inflammation that stimulates differentiation of osteoclasts, a process involving circulating monocytes and T cell-derived factors. The aim of this study was to evaluate relations between circulating monocytes, T cell subsets, and changes in bone characteristics before and after treatment with biological disease-modifying antirheumatic drugs (bDMARDs) in RA.

Methods: Thirty patients with untreated early RA who met the American College of Rheumatology/EULAR 2010 criteria were included. Data were collected before and 48 weeks after treatment with methotrexate (MTX) together with one of three bDMARDs (abatacept, tocilizumab, or certolizumab pegol). Disease activity was measured using the Clinical Disease Activity Index, swollen or tender joint counts, C-reactive protein levels, and erythrocyte sedimentation rates. Proportions of monocyte and CD4 T cell subsets in blood samples were analyzed by flow cytometry. Bone densitometry was performed using high-resolution peripheral quantitative computed tomography (HR-pQCT).

Results: HR-pQCT revealed an overall decrease in cortical (P = 0.009) and trabecular (P = 0.034) bone mineral density, although a subset of patients showed no bone loss after 48 weeks of treatment. The overall bone loss was not associated with age, body mass index, sex, intraarticular glucocorticoid injections, or baseline disease activity. Loss of trabecular bone volume fraction correlated with high proportions of circulating CXCR3Th2 cells (r = -0.38, P = 0.04) and CXCR3Th17 cells (r = -0.36, P = 0.05) at baseline. Similarly, no loss of trabecular bone volume fraction correlated with high proportions of regulatory T cells (r = 0.4, P = 0.03) at baseline. However, the associations were not significant when corrected for confounders and multiple testing.

Conclusion: MTX together with bDMARDs efficiently reduce disease activity but only prevent bone loss in a subset of patients with RA after 48 weeks of treatment. The correlations of circulating baseline T helper cell and regulatory T cell populations with trabecular bone changes suggest a potential novel role for these cells in systemic bone homeostasis during early RA.

References

Feehan L, Li L, McKay H . Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy. BMC Musculoskelet Disord. 2017; 18(1):521. PMC: 5725933. DOI: 10.1186/s12891-017-1888-3. View

Komatsu N, Takayanagi H . Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol. 2012; 3:77. PMC: 3342288. DOI: 10.3389/fimmu.2012.00077. View

Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U . The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 2011; 64(3):671-7. DOI: 10.1002/art.33418. View

Silfversward C, Larsson S, Ohlsson C, Frost A, Nilsson O . Reduced cortical bone mass in mice with inactivation of interleukin-4 and interleukin-13. J Orthop Res. 2007; 25(6):725-31. DOI: 10.1002/jor.20361. View

Johannesdottir F, Putman M, Burnett-Bowie S, Finkelstein J, Yu E, Bouxsein M . Age-Related Changes in Bone Density, Microarchitecture, and Strength in Postmenopausal Black and White Women: The SWAN Longitudinal HR-pQCT Study. J Bone Miner Res. 2021; 37(1):41-51. PMC: 8770571. DOI: 10.1002/jbmr.4460. View

Srirangan S, Choy E . The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2012; 2(5):247-56. PMC: 3383508. DOI: 10.1177/1759720X10378372. View

Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A . Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem. 2005; 281(5):2414-29. DOI: 10.1074/jbc.M510160200. View

Finkelstein J, Brockwell S, Mehta V, Greendale G, Sowers M, Ettinger B . Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2007; 93(3):861-8. PMC: 2266953. DOI: 10.1210/jc.2007-1876. View

Rana A, Li Y, Dang Q, Yang F . Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis. Int Immunopharmacol. 2018; 65:348-359. DOI: 10.1016/j.intimp.2018.10.016. View

10.

Khattab S, El-Saied A, Mohammed R, Mohamed E . CD4+ CD25+ CD127low Regulatory T Cells as Indicator of Rheumatoid Arthritis Disease Activity. Egypt J Immunol. 2017; 23(2):87-95. View

11.

Ruiz-Limon P, Ortega-Castro R, Barbarroja N, Perez-Sanchez C, Jamin C, Patino-Trives A . Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. Front Immunol. 2019; 10:1111. PMC: 6536567. DOI: 10.3389/fimmu.2019.01111. View

12.

Goldring S . Inflammatory signaling induced bone loss. Bone. 2015; 80:143-149. DOI: 10.1016/j.bone.2015.05.024. View

13.

Ahlborg H, Johnell O, Turner C, Rannevik G, Karlsson M . Bone loss and bone size after menopause. N Engl J Med. 2003; 349(4):327-34. DOI: 10.1056/NEJMoa022464. View

14.

Raza K, Falciani F, Curnow S, Ross E, Lee C, Akbar A . Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005; 7(4):R784-95. PMC: 1175027. DOI: 10.1186/ar1733. View

15.

Klose-Jensen R, Tse J, Keller K, Barnabe C, Burghardt A, Finzel S . High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease. Front Med (Lausanne). 2020; 7:337. PMC: 7381125. DOI: 10.3389/fmed.2020.00337. View

16.

Drevinge C, Scheffler J, Koro-Arvidsson C, Sundh D, Carlsten H, Gjertsson I . Intermediate monocytes correlate with CXCR3+ Th17 cells but not with bone characteristics in untreated early rheumatoid arthritis. PLoS One. 2021; 16(3):e0249205. PMC: 7996983. DOI: 10.1371/journal.pone.0249205. View

17.

Yang M, Zhu L . Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis. Int J Mol Sci. 2024; 25(5). PMC: 10931770. DOI: 10.3390/ijms25052688. View

18.

Lee K, Min H, Koh S, Lee S, Kim H, Ju J . Prognostic signature of interferon-γ and interleurkin-17A in early rheumatoid arthritis. Clin Exp Rheumatol. 2021; 40(5):999-1005. DOI: 10.55563/clinexprheumatol/mkbvch. View

19.

Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A . Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology. 2007; 120(4):573-9. PMC: 2265899. DOI: 10.1111/j.1365-2567.2006.02538.x. View

20.

Glinatsi D, Heiberg M, Rudin A, Nordstrom D, Haavardsholm E, Gudbjornsson B . Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label,.... Trials. 2017; 18(1):161. PMC: 5381054. DOI: 10.1186/s13063-017-1891-x. View